Rex,

I guess the only concern about Tysabri and Crohn's would again me the lack of long term safety data. The one patient who died from Tysabri monotherapy was a Crohn's patient and the PML started to appear only after a couple of infusions.

Again, it's benefit vs risk and as long as the patient, be it Crohn's or MS, is given all the information about this, the decision becomes that of the patient.

Harry